Rebranding Langerhans Cell Histiocytosis Disclosure of Relevant Financial Relationships 2017 USCAP/Society for Hematopathology USCAP requires that all planners (Education Committee) in a position to influence or control the content of CME disclose any relevant financial Carl Allen MD, PhD relationship WITH COMMERCIAL INTERESTS which they or their spouse/partner have, or have had, within the past 12 months, which [email protected] relates to the content of this educational activity and creates a conflict of interest.
Disclosures Histiocytoses
• Histiocyte = “Tissue Cell” • Scientific Committee, NovImmune NI‐0501 (IFN‐g antibody) Clinical Trials. • “Classification” is dynamic with changing understanding of biology. • Consultant, Roche. • Classification based on presumed cell of origin. • There are no drugs approved for use in LCH. • Histiocytosis = Abnormal proliferation or function of a “histiocyte”
Classification of Histiocytoses Neoplasms Derived from Histiocytes
• DISORDERS OF VARIED BIOLOGICAL BEHAVIOR 2001 WHO 2008 WHO • Dendritic Cell Proliferation Histiocytic sarcoma Histiocytic sarcoma • Langerhans Cell Histiocytosis LCH Tumors derived from LC • Xanthogranulomas (LCH and LC sarcoma) LC sarcoma • Macrophage Proliferation • Rosai‐Dorfman Disease IDC sarcoma/tumor IDC sarcoma • Sinus histiocytosis with massive lymphadenopathy Follicular DC sarcoma/tumor Follicular DC sarcoma • Hemophagocytic Lymphohistiocytosis DC sarcoma, NOS NOS + Indeterminate DC • “HISTIOCYTIC” MALIGNANCIES • Malignant Histiocytosis Fibroblastic reticular
• Histiocytic Sarcoma Disseminated JXG • AML (M7) Histiocyte Society Writing Group; Favara Med Ped Onc 1997 M Lim, J Hematopath 2009
1 ICD10 “Histiocytoses”
Fernandes, Intl. Arch. Otorhinolaryngol 2009 North American Clinics in Hematology and Oncology, 1998
“…LCH treatment “strategy” is based Epidemiology more on a roulette wheel than on • Children: 5 cases/ 106 scientifically based logic. Certainly part • Adults: 2 cases/ 106 of the confusion and lack of consensus is derived from persisting ambivalence • ALL 34/ 106 as to whether LCH is primarily a • NHL 9/ 106 neoplastic disorder, an • AML 7/ 106 immunodysregulatory disorder, or a 6 disorder with characteristics of both.” • HD 5/ 10 • LCH 5/ 106
North American Clinics in Hematology and Oncology, 1998
“Langerhans Cell” Histiocytosis?
WHAT IS LCH?
1868, On the Nerves of Human Skin
2 What is LCH?
LCH: 1900‐2010
What is LCH? What is LCH?
What is LCH? What is LCH?
Hand‐Christian‐Schuller Eosinophilic granuloma Letterer‐Siwe Hashimoto‐Pritzker Pulmonary LCH
Histiocytosis X Lichtenstein 1953
3 What is LCH? Histiocytosis X CD207 CD1A S100A Fascin Factor XII
Photo courtesy of Dr. John Hicks
Langerhans Cell Histiocytosis
Nezelof et al., 1973 Histology image courtesy of Dr. John Hicks
Langerhans Cells ‐ Basics “Immature‐Activated” Model
CD207+ CD11c+ CD207+ CD11c+ CD1a+ CD1a+
Epidermis Epidermis TNF TNF IFN IFN Draining LN IL1 IL1 IL2 IL2 IL6 IL6 Skin CCR6 Bone CCR7 CCR6 Liver Lung CCR7 E-Cad Lymph node Bone marrow E-Cad Brain
Survival: High vs Low Risk Frequent “Reactivations”
High Risk Low Risk
High Risk
Low Risk
LCHII – Histiocyte Society; Gadner , Blood 2008 Minkov et al., J. Pediatr, 2008
4 Cell‐Specific Gene Expression Experiments PE ‐ Iso Ab
LCH: 2010‐2015 CD207
Iso Ab CD1a‐FITC
LCH CD207+ Transcriptome Suggests Myeloid Dendritic Cell Precursors Immature Myeloid Phenotype in LCH
Increased lin‐CD11c+ in LCH Myeloid DC‐Associated Genes Increased M‐CSF and Flt3L
CD300LF Epidermis ITGAX (CD11c) ITGAM (CD11b) ICAM1 (CD54) CD33 CD1d Dermis ITGA4 (CD49d) Draining LN ANPEP (CD13) CD207 is promiscuous ‐Dermis, Lung, Kidney, Spleen Epidermal LC LCH CD207+ Rolland et al., JI 2005 Ginhoux et al., JEM 2007; Merad, Ginhoux, Collin, Nat Rev Imm 2008 Allen et al., JI, 2010
Shifting Focus: BRAFV600E: The Myeloid Dendritic Cell in LCH A New Piece of the LCH Puzzle
Epidermis
Dermis Draining LN •57% of LCH lesions with BRAFV600E • pMEK and pERK in all cases • No significant clinical correlation with genotype
5 BRAFV600E: Clinical Correlations BRAFV600E in Texas: Clinical Correlations •63% of patients with BRAFV600E
•No significant correlation: V600E • high risk vs low risk WT • age (<2, 2-8, >8 years) • gender Probability of RecurrenceProbability of • single vs multifocal (Weeks) • overall survival
Hazard Ratio: V600E Increased Risk of Recurrence 2.05 (95% CI: 0.99-4.25)
Berres et al., JEM 2014 Berres et al., JEM 2014
Circulating Cells with BRAF‐ BRAF Bar‐Code: V600E in High Risk LCH BRAFV600E in CD11c and CD14 cells
MB0037 8
6
4
2
0 % Circulating Cells with BRAF-V600E Allele BRAF-V600E with Cells % Circulating 0% 13% 100% CD11c CD14 BDCA2 NF (0/26) (5/38) (12/12) Berres et al., JEM 2014 Berres et al., JEM 2014
BRAF Bar‐Code: **50% of “normal” bone marrows BRAF‐V600E in CD34+ cells had BRAF‐V600E+ CD34/precursors
16 16
14 14
12 12
10 10
8 8
6 6
4 4
2 2 % Cells with BRAF-V600E Allele % withCells BRAF-V600E Allele % withCells BRAF-V600E 0 0 CD34 CD14 CD34 CD14 Berres et al., JEM 2014 Berres et al., JEM 2014
6 Expressing V600E in langerin+ DCs BRAF in langerin+ DCs
BRAF in CD11c+ (pre)DCs BRAF in CD11c+ (pre)DCs
Berres et al., JEM 2014
Misguided Myeloid DC Model of LCH VERY Low Mutation Frequency in LCH Patients
Self-renewing Committed DC Committed DC CD1a+/CD207+ N CD34+ stem/progenitor precursors precursors LCH Cells Somatic mutation rate (Per MB x 10 ) (bone marrow) (BM-blood) (tissue) nlmainIfamto Inflammation Inflammation Inflammation
High-risk LCH (multisystem) Median of ONE somatic mutation per LCH sample Low-risk LCH 0.03 muts/MB (multifocal)
Low-risk LCH (single lesion) Pediatric cancers
Collin and Allen, HO Clinic NA 2015 Chakraborty Blood 2014
7 Recurrent MAP2K1 Mutations in LCH More BRAF Mutations in LCH
FUSION
BRAF-V600E MAP2K1 ? INDELS
Brown Blood 2014 Chakraborty Blood 2014 Nelson GCC 2015 Diamond CancDisc 2015 Chakraborty Blood 2016
Genomic Landscape of LCH (2017) Genomic Landscape of Histiocytoses
*ERBB3
RAS
65% BRAFV600E RAF 6% BRAF indel *BRAF Fusion *ARAF 11% Unknown MEK 15% MAP2K1
ERK
+ Fusions: BRAF, ALK, NTRK1 in JXG/ECD LCH
Diamond et al., Canc Discovery 2016
Standard of Care: How Are We Doing?
• LCH-III (High-Risk) • Poor response by Week 12: 30% • Reactivation within 3 Years: 29% Toward Rationale Cure(s) “EFS”=Cure with VBL/Pred: <41%
8 Front‐Line Randomized Trial Front‐Line Randomized Trial LCH-IV (Histiocyte Society) Pilot Trial (N=16) Front-line Cyatarabine: -100% EFS Open Now… -93% 1 Year PFS
LCH REASON Phase III: Pred/Vbl (6MP) 1 vs 2 years Phase III: Pred/Vbl vs Ara-C Front-Line
Open Now…(Texas Chidren’s and 12 Collaborating Sites) N=120 to detect a 20% difference (60 vs 80%) in 1 yr PFS
Simko, BJH 2014
Can We Improve Chemotherapy? Hydroxyurea for LCH?
Goals: Eliminate myeloid neoplastic clone vs control “recurrence”?
Strategy PFS Survival Toxicity Citation
2-CdA 3% (6 month) RO+: 56% Minimal Weitzman (5mg/m2 x 5 day) RO- : 90% 2009
2-CdA/Ara-C 70% (3 year) RO+: 70% (7/10) Universal Bernard (9mg/m2; 1g/m2 x 5 day) 2005 CML Ara-C 60% (1 year) RO+: 100% (6/6) Minimal Simko >75% (100-125 mg/m2 x 5 days) RO-: 100% 2015
Clofarabine 75% (1 year) RO+: 67% (2/3) Minimal Simko (25mg/m2/day x 5 day) RO- : 100% 2014b
Ware, R. Blood. 2010.
Example of Response to HU Salvage – BRAFV600E Inhibition
Prior Treatment: • Ara-C • Clofarabine Vemurafenib in Adult ECD (Haroche JCO 2015) •6MP/MTX Left 9th rib Right T8 Vertebra Objective: Retrospective review of outcomes of patients with Right iliac crest BRAF-V600E+ ECD Splenic uptake Needle biopsy = LCH Primary Response: PET at 6 months -6/6 partial metabolic responders -Response durable with median 10.5 month follow-up
Toxicities: -6/6 with severe skin effects (Grade 2-3) -1/6 with squamous cell carcinoma
Zinn et al., Blood 2016
9 Salvage – BRAFV600E Inhibition Vem in Pediatrics
MSK Basket Trial Hyman et al, NEJM 2015
Toxicity – “C/W other trials”
“NAD” at 10 months No toxicity reported Heretier JAMA Oncology 2015
LCHIV Trial Coming Soon…
NACHO-Clo: (Open) Clofarabine salvage for LR and HR LR Salvage: Pred/VCR/Ara-C with 6MP/MTX + Indomethacin NCI COG MATCH: vs Vemurafenib (BRAF-V600E Inhibitor) Pred/VCR/Ara-C with 6MP/MTX Selumetinib (MEK Inhibitor)
HR Salvage: BASKET: Response after 2 courses Ara-C/2-CDA Multiple novel agents 2nd Generation BRAF Inhibitors ERK Inhibitors PD-1/PD-L1
It’s just LCH…
• Median time to biopsy: >3 mo • % patients with presumed skin-limited with multiystem: 50%
Skin
10 Skin‐limited vs Multisystem Skin‐limited vs Multisystem
Simko J Peds 2014 Simko J Peds 2014
CNS
CNS LCH Skull Lesions: “Clean margins” impair remodeling
A
B
11 Peripheral Blood Progenitors in Peripheral Blood Progenitors in LCH‐ND? LCH‐ND?
Response to BRAFi in LCH‐ND Model: LCH‐ND is LCH Pt 1 Pt2 Pt3 Circulating Tissue-restricted CD1a+/CD207+ CD34+ HSC mDC precursor mDC LCH Lesion DC ND of
High-risk LCH Onset (multisystem)
2 years 4 years 10 years Low-risk LCH
(multifocal) BRAFi ‐ Low-risk LCH Pre (single lesion)
15 mo 8 mo 2 mo Neurodegeneration
BRAFi
On Implications: 1. Treat LCH to eradicate clone. 2. Look for LCH-ND in some systematic fashion (MRI/blood). PR PR NR 3. Treat early unpublished
Lung LCH: A Case of Surgical Cure
Lung
Cytarabine x 12 months
12 Cousins of LCH Cousins of LCH
Allen PBC 2015 Allen PBC 2015
Juvenile Xanthogranuloma Rosai‐Dorfman Disease Sinus Histiocytosis with Massive Lymphadenopathy
Berres Adv Imm 2013; Simko PBC 2014; Chakraborty unpublished
Erdheim‐Chester Disease Evolving Models of Histiocytoses
Haroche et al., Current Opinion Rheumatology 2012; Haroche et al., JCO 2014 Emile et al, Blood 2016; Frater Blood 2016
13 Coffee Break Question Bonus Case • LCH: (Inflammatory) Myeloid Neoplasia? 12 month male with history of skin rash and poor weight gain, now with fever and abdominal distension
Skin bx CD207
Vardiman et al., Blood 2009 Images courtesy of Dr. Choladda Curry
Bonus Case Bonus Case: Bone Marrow
Poor response to vinblastine/prednisone, recurrent fever, abdominal CD1a CD207 distention, sIL2Ra>10k, ferritin>10k CD1a
FactorXIIIa Fascin Bone marrow CD68 CD163
CD163
Bonus Case: Back to Original Skin Bonus Case: Molecular Path
CD1a CD207 BRAF-V600E+ • 3.1% of blood pbmc • 2.5% of bone marrow aspirate pbmc
CD3 CD19 CD16 CD68 CD11c CD11c+CD14 FactorXIIIa Fascin no no yes yes yes yes
Clinical Interpretation: Refractory BRAF-V600E+ mixed histiocytic myeloid neoplastic disorder (LCH + JXG) with reactive macrophage activation
14 Coffee Break Question #2:
• CD1a, CD207, fascin, Factor XIIIa, CD163 for all “LCH”?
• BRAF qPCR (and/or sequencing) for Conclusions all “LCH”?
Back to Histiocytosis X,Y,Z… Pathways to LCH (JXG, ECD, RDD)
*ERBB3
RAS
50-65% BRAF RAF *ARAF CD207 CD34 15-40% Unknown MEK 10-20% MAP2K1
Histiocytosis X ERK
LCH LCH
Histiocytosis X Histiocytosis X Histiocytosis Y Histiocytosis Z
TXCH Histiocytosis Program (BCM) Kenneth McClain, MD, PhD Rikhia Chakraborty, PhD Karen Lim, MS Brooks Scull, MS Dan Zinn MD, Amanda Grimes MD Harshal Abhyankar, MS Ernesto Joubran MS, Aurora Alainis John Hicks MD, PhD Phillip Lupo PhD, Erin Peckham PhD Chris Man PhD, Howard Lin Munu Bilgi, Elizabeth Pacheco Will Parsons MD, PhD, Oliver Hampton PhD David Wheeler PhD Newcastle University Dolores Lopez-Terrada MD, PhD Matthew Collin MD, PhD Singapore Mt. Sinai SOM Florent Ginhoux PhD Miriam Merad MD, PhD UPMC Marie Berres MD Jennifer Picarcic MD Jeremy Price Funding Sources: Brandon Hogstad NCI Lymphoma SPORE (Heslop, PI) Sergio Lira MD, PhD HistioCure Foundation National Cancer Institute (5R01CA154489) Poulikos Poulikakos PhD St. Baldrick’s Consortium Award (NACHO) Juliana Idoyaga PhD ASH Scholar Award University of Zurich Histiocytosis Association Markus Manz MD, PhD Baylor COM Seed Grant University Medical Center Mainz Texas Children’s Hospital Pilot Award Bjorn Clausen Thrasher Research Fund
15